Item 5.02         Departure of Directors or Certain Officers; Election of Directors;
                  Appointment of Certain Officers; Compensatory Arrangements of Certain
                  Officers.



On February 24, 2021, NeoGenomics, Inc. (the "Company") announced Douglas M.
VanOort, its Chairman of the Board and CEO, will retire as Chief Executive
Officer ("CEO") and transition to become Executive Chairman of the Board of
Directors, effective April 19, 2021. The Company also announced that Mark
Mallon, who is currently serving as CEO of Ironwood Pharmaceuticals, Inc.
("Ironwood Pharmaceuticals") through March 12, 2021 and is a former Executive
Vice President of AstraZeneca PLC ("AstraZeneca"), will become NeoGenomics' CEO
and will join the NeoGenomics Board of Directors at that time.
Mr. Mallon has served as CEO of Ironwood Pharmaceuticals since January 2019.
Prior to his role at Ironwood Pharmaceuticals, Mr. Mallon spent twenty-four
years at AstraZeneca in various roles of increasing scope and responsibility,
including serving on the Executive Committee and as Executive Vice President of
Global Product and Portfolio Strategy, Medical Affairs and Corporate Affairs
from 2016 through January 2019. Prior to this role he held several senior sales
and marketing roles at AstraZeneca, including Executive Vice President,
International from 2013 through 2017. Mr. Mallon began his career in the
biopharmaceutical industry in management consulting and earned his B.S. in
chemical engineering from the University of Pennsylvania and an M.B.A. in
marketing and finance from the Wharton School of Business.
On February 23, 2021, the Company and Mr. Mallon entered into an Employment
Agreement which provides that his base salary will be $725,000 per year and that
he will be eligible to receive a performance-based bonus, which will be targeted
at 100% of his base salary. This bonus is contingent on completion of certain
metrics established by the Board of Directors or Compensation Committee for such
fiscal year. Mr. Mallon is also entitled to relocation benefits up to $600,000
in accordance with the Company's relocation policy and such additions as
mutually agreed upon. Mr. Mallon is entitled to participate in all medical and
other benefits that the Company has established for its employees including up
to four weeks of paid time off per year. If Mr. Mallon is terminated without
cause, the Company agrees to maintain his salary for a period of twelve months
and agrees to pay the target bonus Mr. Mallon would have been eligible to
receive for the fiscal year, prorated based on the date of the notice of
termination.
The Employment Agreement also provides that Mr. Mallon will be granted on the
effective date, and with approval from the Board of Directors, an equity grant
in the amount of $5.5 million, to be split equally between restricted shares and
stock options. The number of restricted shares and stock options will be
determined according to the Company's customary practice for valuing equity
grants and the restricted shares and stock options shall each vest ratably over
a period of four years from the date of the grant, so long as Mr. Mallon remains
employed by the Company.
Within six months of the effective date, and subject to Board approval, Mr.
Mallon will be granted a one-time performance-based award equal to a minimum of
$5.0 million in the form of equity and/or cash. This award will be granted based
on the achievement of specified performance metrics established by the
Compensation Committee in consultation with Mr. Mallon and as approved by the
Board. In addition, in 2022 Mr. Mallon will receive an annual equity grant with
an aggregate target value equal to a minimum of $5.0 million. The number of
restricted shares and stock options will be determined according to the
Company's customary practice for valuing equity grants and the restricted shares
and stock options shall each vest ratably over a period of four years from the
date of the grant, so long as Mr. Mallon remains employed by the Company.
Mr. Mallon does not have any related party transactions or family relationships
with the Company or any of the Company's other officers or directors.
The foregoing summary of the Employment Agreement does not purport to be a
complete statement of the terms of the document and is qualified in its entirety
by reference to the full text of the document, a copy of which is being filed
with this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01   Exhibits.



(d) Exhibits

Exhibit No.              Description
                           Employment Agreement between NeoGenomics, Inc. and Mark Mallon dated
10.1                     February 23, 2021
99.1                       Press Release of NeoGenomics, Inc. dated February 24,2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses